STOCK TITAN

Shl Telemedicine Financials

SHMLF
Source SEC Filings (10-K/10-Q) Updated Dec 31, 2024 Currency USD FYE December

This page shows Shl Telemedicine (SHMLF) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Profitability Growth Leverage Liquidity Cash Flow Returns 33 / 100
Financial Profile 33/100

Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores

Growth
32

Shl Telemedicine's revenue declined 0.5% year-over-year, from $57.1M to $56.8M. This contraction results in a growth score of 32/100.

Leverage
100

Shl Telemedicine carries a low D/E ratio of 0.09, meaning only $0.09 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity
16

Shl Telemedicine's current ratio of 1.04 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 16/100, which could limit financial flexibility.

Cash Flow
19

While Shl Telemedicine generated -$372K in operating cash flow, capex of $950K consumed most of it, leaving -$1.3M in free cash flow. This results in a low score of 19/100, reflecting heavy capital investment rather than weak cash generation.

Returns
0

Shl Telemedicine generates a -70.7% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -9.0% the prior year.

Piotroski F-Score Weak
3/9

Shl Telemedicine passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality
0.01x

For every $1 of reported earnings, Shl Telemedicine generates $0.01 in operating cash flow (-$372K OCF vs -$27.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$56.8M
YoY-0.5%

Shl Telemedicine generated $56.8M in revenue in fiscal year 2024. This represents a decrease of 0.5% from the prior year.

EBITDA
N/A
Net Income
-$27.8M
YoY-304.9%

Shl Telemedicine reported -$27.8M in net income in fiscal year 2024. This represents a decrease of 304.9% from the prior year.

EPS (Diluted)
N/A

Cash & Balance Sheet

Free Cash Flow
-$1.3M
YoY+52.5%

Shl Telemedicine generated -$1.3M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 52.5% from the prior year.

Cash & Debt
$7.7M
YoY+14.7%

Shl Telemedicine held $7.7M in cash against $3.6M in long-term debt as of fiscal year 2024.

Dividends Per Share
N/A
Shares Outstanding
16M
YoY+0.0%

Shl Telemedicine had 16M shares outstanding in fiscal year 2024. This represents an increase of 0.0% from the prior year.

Margins & Returns

Gross Margin
N/A
Operating Margin
N/A
Net Margin
-48.9%
YoY-36.9pp

Shl Telemedicine's net profit margin was -48.9% in fiscal year 2024, showing the share of revenue converted to profit. This is down 36.9 percentage points from the prior year.

Return on Equity
-70.7%
YoY-61.7pp

Shl Telemedicine's ROE was -70.7% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 61.7 percentage points from the prior year.

Capital Allocation

R&D Spending
N/A
Share Buybacks
N/A
Capital Expenditures
$950K
YoY-26.3%

Shl Telemedicine invested $950K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 26.3% from the prior year.

SHMLF Income Statement

Metric Q4'24 Q2'24 Q4'23 Q2'23 Q4'22 Q2'22 Q4'21
Revenue N/A N/A N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A N/A N/A
Gross Profit N/A N/A N/A N/A N/A N/A N/A
R&D Expenses N/A N/A N/A N/A N/A N/A N/A
SG&A Expenses N/A N/A N/A N/A N/A N/A N/A
Operating Income N/A N/A N/A N/A N/A N/A N/A
Interest Expense N/A N/A N/A N/A N/A N/A N/A
Income Tax N/A N/A N/A N/A N/A N/A N/A
Net Income N/A N/A N/A N/A N/A N/A N/A
EPS (Diluted) N/A N/A N/A N/A N/A N/A N/A

SHMLF Balance Sheet

Metric Q4'24 Q2'24 Q4'23 Q2'23 Q4'22 Q2'22 Q4'21
Total Assets $80.8M-21.5% $102.8M-9.0% $113.0M-5.7% $119.8M+8.2% $110.8M-3.1% $114.3M-11.8% $129.6M
Current Assets $27.5M-17.0% $33.1M-17.3% $40.1M-9.8% $44.4M+37.5% $32.3M-16.3% $38.6M-15.8% $45.9M
Cash & Equivalents $7.7M-29.5% $10.9M+62.7% $6.7M-35.9% $10.4M+132.8% $4.5M-72.7% $16.4M+10.6% $14.8M
Inventory $1.2M-59.6% $2.9M-16.1% $3.5M-13.4% $4.0M+3.0% $3.9M-21.7% $5.0M+17.9% $4.2M
Accounts Receivable N/A N/A N/A N/A N/A N/A N/A
Goodwill $19.1M-39.9% $31.8M-3.5% $33.0M+2.0% $32.3M-4.2% $33.7M+0.9% $33.4M-10.9% $37.5M
Total Liabilities $41.5M+27.4% $32.6M-11.0% $36.6M-9.0% $40.2M-21.9% $51.5M-12.2% $58.6M-14.8% $68.8M
Current Liabilities $26.5M+74.2% $15.2M-12.6% $17.4M+9.8% $15.9M-10.9% $17.8M+10.2% $16.2M-6.9% $17.4M
Long-Term Debt $3.6M-22.6% $4.6M-3.6% $4.8M-45.7% $8.8M-4.9% $9.3M-0.2% $9.3M-16.7% $11.2M
Total Equity $39.2M-44.1% $70.3M-8.1% $76.5M-4.0% $79.6M+34.3% $59.3M+6.5% $55.7M-8.4% $60.8M
Retained Earnings -$108.2M-28.6% -$84.1M-5.0% -$80.1M-6.4% -$75.3M-3.0% -$73.1M-0.1% -$73.0M0.0% -$73.0M

SHMLF Cash Flow Statement

Metric Q4'24 Q2'24 Q4'23 Q2'23 Q4'22 Q2'22 Q4'21
Operating Cash Flow N/A N/A N/A N/A N/A N/A N/A
Capital Expenditures N/A N/A N/A N/A N/A N/A N/A
Free Cash Flow N/A N/A N/A N/A N/A N/A N/A
Investing Cash Flow N/A N/A N/A N/A N/A N/A N/A
Financing Cash Flow N/A N/A N/A N/A N/A N/A N/A
Dividends Paid N/A N/A N/A N/A N/A N/A N/A
Share Buybacks N/A N/A N/A N/A N/A N/A N/A

SHMLF Financial Ratios

Metric Q4'24 Q2'24 Q4'23 Q2'23 Q4'22 Q2'22 Q4'21
Gross Margin N/A N/A N/A N/A N/A N/A N/A
Operating Margin N/A N/A N/A N/A N/A N/A N/A
Net Margin N/A N/A N/A N/A N/A N/A N/A
Return on Equity N/A N/A N/A N/A N/A N/A N/A
Return on Assets N/A N/A N/A N/A N/A N/A N/A
Current Ratio 1.04-1.1 2.17-0.1 2.30-0.5 2.80+1.0 1.81-0.6 2.39-0.3 2.64
Debt-to-Equity 0.09+0.0 0.070.0 0.06-0.0 0.11-0.0 0.16-0.0 0.17-0.0 0.18
FCF Margin N/A N/A N/A N/A N/A N/A N/A

Frequently Asked Questions

Shl Telemedicine (SHMLF) reported $56.8M in total revenue for fiscal year 2024. This represents a -0.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Shl Telemedicine (SHMLF) revenue declined by 0.5% year-over-year, from $57.1M to $56.8M in fiscal year 2024.

No, Shl Telemedicine (SHMLF) reported a net income of -$27.8M in fiscal year 2024, with a net profit margin of -48.9%.

As of fiscal year 2024, Shl Telemedicine (SHMLF) had $7.7M in cash and equivalents against $3.6M in long-term debt.

Shl Telemedicine (SHMLF) had a net profit margin of -48.9% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

Shl Telemedicine (SHMLF) has a return on equity of -70.7% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

Shl Telemedicine (SHMLF) generated -$1.3M in free cash flow during fiscal year 2024. This represents a 52.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Shl Telemedicine (SHMLF) generated -$372K in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

Shl Telemedicine (SHMLF) had $80.8M in total assets as of fiscal year 2024, including both current and long-term assets.

Shl Telemedicine (SHMLF) invested $950K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

Shl Telemedicine (SHMLF) had 16M shares outstanding as of fiscal year 2024.

Shl Telemedicine (SHMLF) had a current ratio of 1.04 as of fiscal year 2024, which is considered adequate.

Shl Telemedicine (SHMLF) had a debt-to-equity ratio of 0.09 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

Shl Telemedicine (SHMLF) had a return on assets of -34.4% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2024 data, Shl Telemedicine (SHMLF) had $7.7M in cash against an annual operating cash burn of $372K. This gives an estimated cash runway of approximately 248 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Shl Telemedicine (SHMLF) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Shl Telemedicine (SHMLF) has an earnings quality ratio of 0.01x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Shl Telemedicine (SHMLF) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.

Back to top